IP Library Granted Patent US 7,015,250
Granted Patent B2
US 7,015,250 · App. 09/781,491 · Granted Mar 21, 2006

Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid

Assignee: Glykon Technologies Group, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,015,250
App. No.
09/781,491
Granted
Mar 21, 2006
Kind
B2
Abstract

A method whereby the blood pressure metabolism in an individual showing evidence of dysregulation is improved when that person receives an appropriate oral administration of (−)-hydroxycitric acid. The potassium salt of (−)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other derivatives of the acid. The regulation of blood pressure levels over any given period of time may be improved with a controlled release form of (−)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypotensive agent.

Claims (18)

1. A method for treating or ameliorating hypertension or high blood pressure in individuals in need thereof which is comprised of administering orally an effective amount of (−)-hydroxycitric acid.

2. A method for treating or ameliorating hypertension or high blood pressure by lowering elevated insulin in individuals in need thereof which is comprised of administering orally an effective amount of (−)-hydroxycitric acid.

3. A method for treating or ameliorating hypertension or high blood pressure by lowering elevated glucocorticoid levels in individuals in need thereof which is comprised of administering orally an effective amount of (−)-hydroxycitric acid.

4. The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the free acid or its lactone.

5. The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkali metal salts potassium or sodium (−)-hydroxycitrate.

6. The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkaline earth metal salts calcium or magnesium (−)-hydroxycitrate.

7. The method of claim 1 where (−)-hydroxycitric acid is supplied as a therapeutically effective amount of a mixture the alkali metal salts and/or the alkaline earth metals of (−)-hydroxycitrate or some mixture of alkali metal salts and alkaline earth metal salts of (−)-hydroxycitrate or in the form of therapeutically effective amide and/or ester derivatives of (−)-hydroxycitric acid.

8. The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount as the free acid, its lactone or as one or more of the salts or other derivatives of the free acid and is delivered in a controlled release form.

9. The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the free acid or its lactone.

10. The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkali metal salts potassium or sodium (−)-hydroxycitrate.

11. The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkaline earth metal salts calcium or magnesium (−)-hydroxycitrate.

12. The method of claim 2 where (−)-hydroxycitric acid is supplied as a therapeutically effective amount of a mixture the alkali metal salts and/or the alkaline earth metals of (−)-hydroxycitrate or some mixture of alkali metal salts and alkaline earth metal salts of (−)-hydroxycitrate or in the form of therapeutically effective amide and/or ester derivatives of (−)-hydroxycitric acid.

13. The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount as the free acid, its lactone or as one or more of the salts or other derivatives of the free acid and is delivered in a controlled release form.

14. The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the free acid or its lactone.

15. The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkali metal salts potassium or sodium (−)-hydroxycitrate.

16. The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkaline earth metal salts calcium or magnesium (−)-hydroxycitrate.

17. The method of claim 3 where (−)-hydroxycitric acid is supplied as a therapeutically effective amount of a mixture the alkali metal salts and/or the alkaline earth metals of (−)-hydroxycitrate or some mixture of alkali metal salts and alkaline earth metal salts of (−)-hydroxycitrate or in the form of therapeutically effective amide and/or ester derivatives of (−)-hydroxycitric acid.

18. The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount as the free acid, its lactone or as one or more of the salts or other derivatives of the free acid and is delivered in a controlled release form.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2015
From: FOLEY & LARDNER LLP
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 036197/0768 →
SECURITY AGREEMENT Recorded Feb 28, 2011
From: GLYKON TECHNOLOGIES GROUP, LLC
To: FOLEY & LARDNER LLP
Reel/Frame 025858/0828 →
ASSIGNMENT AND QUITCLAIM Recorded Apr 9, 2007
From: RENAISSANCE HERBS, INC.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 019140/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2004
From: CLOUATRE, DALLAS L.; DUNN, JAMES M.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 016015/0444 →
Continuity (2)
Provisional Application 6018128500 · Feb 9, 2000
Related Publication 20010044469A1 · Nov 22, 2001